Now that stand-alone HPV tests have been approved, is it worth changing cervical cancer screening recommendations? Juan Felix, MD, weighs in.
The use of intraperitoneal chemotherapy for the treatment of advanced ovarian cancer resulted in a survival benefit over intravenous chemotherapy.
The GnRH agonist goserelin, when given during chemotherapy, may protect against ovarian failure and early menopause in women with breast cancer.
Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.
Hormone replacement therapy won't protect postmenopausal women against stroke or heart disease, but don't discount it for symptoms of menopause just yet.
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.
Clinicians conducting breast examinations who don’t apply enough force during palpation risk missing deeper lesions.
A new study yielded nomograms for the assessment of locally advanced cervical cancer, with prognostic factors including histology, performance status, and others.
Genetic testing for ovarian or endometrial cancer isn't recommended for everyone. Find out here which patients should be referred for testing.